An mRNA Vaccine against SARS-CoV-2

Moderna has completed their Phase I Trial in the U.S. of their mRNA-1273 vaccine. The results are promising. It induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine.  The Phase II trial is underway with results expected by late August. At that point, it will move to a Phase III Trial which will test safety and efficacy in much larger populations. NCT04283461.  

_________________

EDITORIAL

Covid-19 Vaccine-Development Multiverse

  • Penny M. Heaton, M.D.

____________________

Characteristics of Persons Who Died with COVID-19

An early release MMWR outlines characteristics of people who died with laboratory-confirmed COVID-19 and was obtained through CDC’s case-based surveillance data and supplemental surveillance data from 16 public health jurisdictions.

_________________________

MMWR: Factors Associated with Cloth Face Covering Use Among Adults During the COVID-19 Pandemic 

Another early release MMWR discusses the findings of two internet surveys that assessed a sample of adults’ use of cloth face coverings and the behavioral and sociodemographic factors that might influence wearing a cloth face-covering out in public.

Within days of the release of the first national recommendation for use of cloth face coverings, most people who reported leaving their home in the previous week reported using a cloth face covering.

Related Post